PE20191787A1 - Derivados de indol n-sustituidos - Google Patents
Derivados de indol n-sustituidosInfo
- Publication number
- PE20191787A1 PE20191787A1 PE2019002413A PE2019002413A PE20191787A1 PE 20191787 A1 PE20191787 A1 PE 20191787A1 PE 2019002413 A PE2019002413 A PE 2019002413A PE 2019002413 A PE2019002413 A PE 2019002413A PE 20191787 A1 PE20191787 A1 PE 20191787A1
- Authority
- PE
- Peru
- Prior art keywords
- indol
- methyl
- substitute derivatives
- compound
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Referido a derivados de indol N-sustituidos, un compuesto de formula I, en donde R1 es H o metilo; R2 es metilo, Br, Cl o ciano; o una sal farmaceutica aceptable del mismo. Un compuesto preferido es: acido 4-{6-[2-(2-metil-indol-1-il)-etilamino]-pirimidin-4-il}-benzoico. Estos compuestos son moduladores del receptor EP2 de la prostaglandina 2. Tambien se refiere a metodos para su preparacion, y su uso como composicion farmaceutica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017062008 | 2017-05-18 | ||
| PCT/EP2018/062865 WO2018210995A1 (en) | 2017-05-18 | 2018-05-17 | N-substituted indole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191787A1 true PE20191787A1 (es) | 2019-12-24 |
Family
ID=62186481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019002413A PE20191787A1 (es) | 2017-05-18 | 2018-05-17 | Derivados de indol n-sustituidos |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US20200069686A1 (es) |
| EP (1) | EP3625224B1 (es) |
| JP (1) | JP7065117B2 (es) |
| KR (1) | KR102650756B1 (es) |
| CN (1) | CN110621666A (es) |
| AR (1) | AR111806A1 (es) |
| AU (1) | AU2018269667B2 (es) |
| BR (1) | BR112019024114A2 (es) |
| CA (1) | CA3063637A1 (es) |
| CL (1) | CL2019003257A1 (es) |
| CO (1) | CO2019010804A2 (es) |
| CR (1) | CR20190567A (es) |
| CY (1) | CY1124528T1 (es) |
| DK (1) | DK3625224T3 (es) |
| EA (1) | EA039630B1 (es) |
| ES (1) | ES2894124T3 (es) |
| HR (1) | HRP20211532T1 (es) |
| HU (1) | HUE056406T2 (es) |
| IL (1) | IL270616B (es) |
| LT (1) | LT3625224T (es) |
| MA (1) | MA49127B1 (es) |
| MX (1) | MX394108B (es) |
| PE (1) | PE20191787A1 (es) |
| PH (1) | PH12019502562B1 (es) |
| PL (1) | PL3625224T3 (es) |
| PT (1) | PT3625224T (es) |
| RS (1) | RS62441B1 (es) |
| SG (1) | SG11201908660RA (es) |
| SI (1) | SI3625224T1 (es) |
| TW (1) | TWI768043B (es) |
| UA (1) | UA124748C2 (es) |
| WO (1) | WO2018210995A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| PL3625228T3 (pl) | 2017-05-18 | 2021-12-20 | Idorsia Pharmaceuticals Ltd | Pochodne pirymidyny jako modulatory receptora pge2 |
| IL270623B2 (en) | 2017-05-18 | 2023-03-01 | Idorsia Pharmaceuticals Ltd | History of phenyl as pge2 receptor modulators |
| AR111807A1 (es) | 2017-05-18 | 2019-08-21 | Idorsia Pharmaceuticals Ltd | Derivados de benzofurano y benzotiofeno como moduladores del receptor pge2 |
| JP7253500B2 (ja) | 2017-05-18 | 2023-04-06 | イドーシア ファーマシューティカルズ リミテッド | ピリミジン誘導体 |
| WO2021060281A1 (ja) * | 2019-09-24 | 2021-04-01 | Ａｇｃ株式会社 | プロスタグランジンｅ２レセプターｅｐ２／ｅｐ４デュアルアンタゴニスト |
| CN115697317A (zh) * | 2020-04-08 | 2023-02-03 | 株式会社AskAt | Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用 |
| US20230390303A1 (en) | 2020-11-13 | 2023-12-07 | Ono Pharmaceutical Co., Ltd. | Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor |
| WO2025229177A1 (en) | 2024-05-02 | 2025-11-06 | Idorsia Pharmaceuticals Ltd | Crystalline forms of an n-substituted indole derivative |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1267867B1 (en) | 2000-03-24 | 2008-05-14 | Asterand Uk Limited | Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists |
| HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| GB0031302D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Napthalene derivatives |
| GB0031295D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Naphthalene derivatives |
| GB0103269D0 (en) | 2001-02-09 | 2001-03-28 | Glaxo Group Ltd | Napthalene derivatives |
| BR0309188A (pt) | 2002-04-12 | 2005-02-09 | Pfizer | Compostos pirazolo como agentes antiinflamatórios e analgésicos |
| WO2003086390A1 (en) | 2002-04-12 | 2003-10-23 | Pfizer Japan Inc. | Imidazole compounds as anti-inflammatory and analgesic agents |
| US20040023853A1 (en) | 2002-05-23 | 2004-02-05 | Peri Krishna G. | Antagonistic peptides of prostaglandin E2 receptor subtype EP4 |
| ATE396182T1 (de) | 2003-01-29 | 2008-06-15 | Asterand Uk Ltd | Hemmstoffe des ep4-rezeptors |
| PE20050347A1 (es) * | 2003-08-26 | 2005-05-04 | Teijin Pharma Ltd | Derivados de pirrolopirimidina |
| MXPA06002551A (es) | 2003-09-03 | 2006-06-20 | Pfizer | Compuestos de aril o heteroaril amida. |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| EA200601847A1 (ru) | 2004-05-04 | 2007-04-27 | Пфайзер Инк. | Замещённые метиларил- или гетероариламидные соединения |
| AP2006003769A0 (en) | 2004-05-04 | 2006-10-31 | Pfizer | Ortho substituted aryl or heteroaryl amide compounds |
| GT200500284A (es) | 2004-10-15 | 2006-03-27 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| JP5289046B2 (ja) | 2005-05-19 | 2013-09-11 | メルク カナダ インコーポレイテッド | Ｅｐ４アンタゴニストとしてのキノリン誘導体 |
| WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| US7968578B2 (en) | 2006-04-24 | 2011-06-28 | Merck Frosst Canada Ltd. | Indole amide derivatives as EP4 receptor antagonists |
| AU2007260529B2 (en) | 2006-06-12 | 2012-04-19 | Merck Canada Inc. | Indoline amide derivatives as EP4 receptor ligands |
| WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
| EP2044056B1 (en) | 2006-07-14 | 2012-08-22 | Novartis AG | Pyrimidine derivatives as alk-5 inhibitors |
| ES2421453T3 (es) | 2006-08-11 | 2013-09-02 | Merck Frosst Canada Ltd | Derivados de tiofenocarboxamida como ligandos del receptor EP4 |
| WO2008039882A1 (en) | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
| EP2114877B1 (en) | 2007-02-26 | 2012-12-26 | Merck Canada Inc. | Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists |
| CN101636385B (zh) | 2007-03-26 | 2012-09-05 | 默克弗罗斯特加拿大有限公司 | 作为ep4受体拮抗剂的萘和喹啉磺酰脲衍生物 |
| US8030489B2 (en) | 2007-03-26 | 2011-10-04 | Astellas Pharma Inc. | Ornithine derivative |
| EP2014657A1 (de) * | 2007-06-21 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Diaminopyrimidine als Modulatoren des EP2-Rezeptors |
| JP5408434B2 (ja) | 2007-07-03 | 2014-02-05 | アステラス製薬株式会社 | アミド化合物 |
| RU2479576C9 (ru) | 2008-05-14 | 2014-03-10 | Астеллас Фарма Инк. | Амидное соединение |
| US8404736B2 (en) | 2008-08-14 | 2013-03-26 | Beta Pharma Canada Inc. | Heterocyclic amide derivatives as EP4 receptor antagonists |
| GB2474813B (en) | 2008-09-19 | 2014-05-28 | Biotechnology Res Corp Ltd | Triterpenoid compounds and methods of use thereof |
| JP2012503605A (ja) | 2008-09-25 | 2012-02-09 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体アンタゴニストとしてのベータ−カルボリンスルホニルウレア誘導体 |
| US8927547B2 (en) | 2010-05-21 | 2015-01-06 | Noviga Research Ab | Pyrimidine derivatives |
| EP2619182B1 (en) | 2010-09-21 | 2016-11-09 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition |
| JP5273689B2 (ja) | 2010-09-29 | 2013-08-28 | 株式会社エヌビィー健康研究所 | ヒトプロスタグランジンｅ２受容体ｅｐ４に対する抗体 |
| US8828987B2 (en) | 2010-12-10 | 2014-09-09 | Rottapharm Biotech S.R.L. | Pyridine amide derivatives as EP4 receptor antagonists |
| WO2012103071A2 (en) | 2011-01-25 | 2012-08-02 | Eisai R&D Management Co., Ltd. | Compounds and compositions |
| US9006241B2 (en) | 2011-03-24 | 2015-04-14 | Noviga Research Ab | Pyrimidine derivatives |
| BR112014000087B1 (pt) | 2011-07-04 | 2021-08-17 | Rottapharm Biotech S.R.L. | Derivados de amina cíclica como antagonistas do receptor ep4 |
| EP2554662A1 (en) | 2011-08-05 | 2013-02-06 | M Maria Pia Cosma | Methods of treatment of retinal degeneration diseases |
| WO2013090552A1 (en) | 2011-12-13 | 2013-06-20 | Yale University | Compositions and methods for reducing ctl exhaustion |
| US9296701B2 (en) | 2012-04-24 | 2016-03-29 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
| AR091429A1 (es) | 2012-06-29 | 2015-02-04 | Lilly Co Eli | Compuestos de fenoxietil piperidina |
| TWI572597B (zh) | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | 二甲基－苯甲酸化合物 |
| UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| EP2765128A1 (en) | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Substituted benzamides with activity towards EP4 receptors |
| TW201443004A (zh) | 2013-02-15 | 2014-11-16 | Lilly Co Eli | 苯氧基乙氧基化合物 |
| TWI636046B (zh) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫－１ｈ－異喹啉化合物 |
| BR112015030315B1 (pt) | 2013-06-12 | 2022-10-04 | Kaken Pharmaceutical Co., Ltd | Derivado de 4-alquinilimidazol e produto farmacêutico que o compreende e antagonista de receptor de ep4 |
| KR102276644B1 (ko) | 2013-09-04 | 2021-07-13 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조절제로서 유용한 화합물 |
| HRP20181052T1 (hr) | 2013-09-06 | 2018-09-07 | Aurigene Discovery Technologies Limited | Derivati 1,2,4-oksadiazola kao imunomodulatori |
| WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
| CA2927392C (en) | 2013-10-17 | 2021-11-09 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
| PL3083554T3 (pl) | 2013-12-17 | 2019-08-30 | Eli Lilly & Company | Związki kwasu dimetylobenzoesowego |
| PL3083562T3 (pl) | 2013-12-17 | 2018-02-28 | Eli Lilly & Company | Pochodne fenoksyetylowych cyklicznych amin i ich aktywność jako modulatorów receptora EP4 |
| TW201607943A (zh) | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ｅｐ４配體之新穎苯并咪唑衍生物 |
| TW201623277A (zh) | 2014-03-26 | 2016-07-01 | 安斯泰來製藥股份有限公司 | 醯胺化合物 |
| KR102535283B1 (ko) | 2014-05-23 | 2023-05-22 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 암의 치료를 위한 조합 요법 |
| WO2016021742A1 (en) | 2014-08-07 | 2016-02-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds as ep4 receptor antagonists |
| WO2016054807A1 (en) * | 2014-10-10 | 2016-04-14 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
| CN107108480B (zh) | 2015-01-09 | 2020-01-17 | 小野药品工业株式会社 | 三环螺环化合物 |
| WO2017014323A1 (en) | 2015-07-23 | 2017-01-26 | Takeda Pharmaceutical Company Limited | 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists |
| MX390051B (es) | 2015-10-16 | 2025-03-20 | Eisai R&D Man Co Ltd | Antagonistas de ep4. |
-
2018
- 2018-05-17 SG SG11201908660R patent/SG11201908660RA/en unknown
- 2018-05-17 PL PL18725223T patent/PL3625224T3/pl unknown
- 2018-05-17 LT LTEPPCT/EP2018/062865T patent/LT3625224T/lt unknown
- 2018-05-17 HU HUE18725223A patent/HUE056406T2/hu unknown
- 2018-05-17 CA CA3063637A patent/CA3063637A1/en active Pending
- 2018-05-17 MX MX2019013639A patent/MX394108B/es unknown
- 2018-05-17 AR ARP180101311A patent/AR111806A1/es not_active Application Discontinuation
- 2018-05-17 DK DK18725223.4T patent/DK3625224T3/da active
- 2018-05-17 EP EP18725223.4A patent/EP3625224B1/en active Active
- 2018-05-17 PH PH1/2019/502562A patent/PH12019502562B1/en unknown
- 2018-05-17 UA UAA201911973A patent/UA124748C2/uk unknown
- 2018-05-17 ES ES18725223T patent/ES2894124T3/es active Active
- 2018-05-17 CN CN201880031869.9A patent/CN110621666A/zh active Pending
- 2018-05-17 PT PT18725223T patent/PT3625224T/pt unknown
- 2018-05-17 WO PCT/EP2018/062865 patent/WO2018210995A1/en not_active Ceased
- 2018-05-17 AU AU2018269667A patent/AU2018269667B2/en not_active Ceased
- 2018-05-17 SI SI201830413T patent/SI3625224T1/sl unknown
- 2018-05-17 RS RS20211259A patent/RS62441B1/sr unknown
- 2018-05-17 JP JP2019563494A patent/JP7065117B2/ja not_active Expired - Fee Related
- 2018-05-17 US US16/614,268 patent/US20200069686A1/en not_active Abandoned
- 2018-05-17 KR KR1020197037058A patent/KR102650756B1/ko active Active
- 2018-05-17 EA EA201992679A patent/EA039630B1/ru unknown
- 2018-05-17 HR HRP20211532TT patent/HRP20211532T1/hr unknown
- 2018-05-17 PE PE2019002413A patent/PE20191787A1/es unknown
- 2018-05-17 TW TW107116708A patent/TWI768043B/zh not_active IP Right Cessation
- 2018-05-17 BR BR112019024114-0A patent/BR112019024114A2/pt not_active Application Discontinuation
- 2018-05-17 MA MA49127A patent/MA49127B1/fr unknown
- 2018-05-17 CR CR20190567A patent/CR20190567A/es unknown
-
2019
- 2019-09-30 CO CONC2019/0010804A patent/CO2019010804A2/es unknown
- 2019-11-13 IL IL270616A patent/IL270616B/en unknown
- 2019-11-14 CL CL2019003257A patent/CL2019003257A1/es unknown
-
2021
- 2021-09-27 CY CY20211100841T patent/CY1124528T1/el unknown
-
2022
- 2022-11-27 US US18/058,873 patent/US20230165859A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191787A1 (es) | Derivados de indol n-sustituidos | |
| CY1124913T1 (el) | Ν-υποκατεστημενα παραγωγα ινδολης ως διαμορφωτες υποδοχεα pge2 | |
| PE20221336A1 (es) | Compuestos triciclicos sustituidos | |
| PE20252338A1 (es) | Compuesto agonista de receptor thrb y metodo de preparacion | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| EA200901379A1 (ru) | Производные никотиновой кислоты как модуляторы метаботропных глутаматных рецепторов 5 подтипа | |
| CO6280476A2 (es) | Derivados de alcanos azabiciclicos sustituidos con biarilo como moduladores de la actividad de los receptores nicotinicos de acetilcolina | |
| PE20142019A1 (es) | Nuevos derivados de acidos indaniloxidihidrobenzofuranilaceticos y sus usos como agonistas del receptor gpr40 | |
| AR085149A1 (es) | Moduladores del receptor de glucagon | |
| CY1124608T1 (el) | Παραγωγα φαινυλιου ως ρυθμιστες υποδοχεα pge2 | |
| AR090488A1 (es) | Derivados de n-ciclobutilbenzamida, un proceso para su obtencion, intermediarios para su sintesis, composiciones pesticidas y farmaceuticas que los comprenden y metodos para controlar daños debidos a una plaga y/u hongos | |
| PE20211472A1 (es) | Derivados de 2-(feniloxi o feniltio)pirimidina como herbicidas | |
| EA201990388A1 (ru) | Пиперидиновые модуляторы рецепторов cxcr7 | |
| AR080056A1 (es) | Derivados de ciclohexil-amida como antagonistas de los receptores de crf | |
| PE20171057A1 (es) | Derivados espirodiamina como inhibidores de la aldosterona sintasa | |
| AR069480A1 (es) | Derivados de 2-amino-pirimidina | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| CL2016001023A1 (es) | Compuesto n-(1-(4-(2-(4-cloro-2,6-dimetilpirimidin-5-il)etil)piperidin-1-il)-1-oxopropan-2-il)ciclopropanocarboxamida, estereoisomero, inhibidores de grelina o-aciltransferasa (goat); composición farmaceutica; y uso para reducir la ganancia de peso y para tratar la diabetes tipo 2. | |
| PE20170684A1 (es) | Derivados de heterociclilo opcionalmente condensados de pirimidina utiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncologicas y autoinmunitarias | |
| PE20170946A1 (es) | 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| EP3952865A4 (en) | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS FOR THERAPEUTIC USES | |
| AR068115A1 (es) | Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida | |
| PE20191032A1 (es) | Pirido[3,4-b]indoles sustituidos para tratamiento de los trastornos de los cartilagos | |
| MX394835B (es) | Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol. | |
| MY161403A (en) | 5- (phenyl/pyridinyl-ethinyl) -2-pyridine/ 2-pyrimidine-carborxamides as mglur5 modulators |